€186.4m market cap
€2.13 last close
Acacia Pharma is a commercial-stage biopharmaceutical company developing and commercialising novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures or chemotherapy. BARHEMSYS is approved for PONV in the US and in-licensed asset BYFAVO is approved for PS.
Investment summary
Acacia Pharma is focused on bringing antiemetic drugs to the US hospital setting for unmet needs in post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting. Its lead product, BARHEMSYS (reformulated amisulpride for the management of PONV), received FDA approval with a broad label in February 2020. Under the deal with Cosmo Pharmaceuticals, Acacia was assigned the US licence for Paion’s sedative BYFAVO (remimazolam), which received FDA approval for procedural sedation (PS) in July 2020. Acacia plans to launch both BARHEMSYS and BYFAVO in H220 and has been building up its US commercial operations in preparation. At 30 June 2020, Acacia had net cash of $21.9m. A share placing in August that raised €25m gross plus access to a €25m loan facility from Cosmo following BYFAVO approval enables Acacia to expand its US commercial infrastructure to support both product launches.
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2018A | 0.0 | (20.0) | (21.6) | (45.46) | N/A | N/A |
| 2019A | 0.0 | (22.4) | (23.5) | (37.17) | N/A | N/A |
| 2020E | 2.1 | (32.5) | (36.2) | (40.06) | N/A | N/A |
| 2021E | 28.8 | (38.3) | (40.0) | (46.17) | N/A | N/A |
Industry outlook
Inadequately treated PONV leads to prolonged stays in post-anaesthesia care unit recovery rooms. Use of BARHEMSYS could reduce patient hospitalisation time and the associated costs. Likewise, BYFAVO can reduce the time required for invasive medical procedures, enabling increased patient throughput for hospitals and surgical centres.
Last updated on 20/10/2020
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net cash (US$m) | 13.2 |
| Forecast gearing ratio (%) | N/A |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| Michael Bolinder | CEO |
| Gary Gemignani | CFO |
You may also be interested in…
- 4SC
- Abliva
- Acarix
- ADL Bionatur Solutions
- Adocia
- Allarity Therapeutics
- ASIT biotech
- Basilea Pharmaceutica
- BioPorto Diagnostics
- Bonesupport
- Brighter
- Cantargia
- Carmat
- Celyad
- Deinove
- Formycon
- Herantis Pharma
- Hybrigenics
- Immunicum
- Immunovia
- Kiadis Pharma
- Laboratorios Farmacéuticos ROVI
- MagForce
- Medigene
- MOLOGEN
- Nanobiotix
- Newron Pharmaceuticals
- Nuevolution
- Oasmia Pharmaceutical
- Onxeo
- Orexo
- Oryzon Genomics
- OSE Immunotherapeutics
- Paion
- Pharnext
- Photocure
- Pixium Vision
- Polyphor
- Probiodrug
- Quantum Genomics
- RhoVac
- Ryvu Therapeutics
- Targovax
- Transgene
- TxCell
- Xbrane Biopharma